DIRAS1 and colorectal carcinoma: While promoter methylation-mediated suppression represents a well-established paradigm [44], our data suggest that in specific CRC subtypes, particularly those with acquired chemoresistance, DIRAS1 is upregulated and exerts pro-tumorigenic functions.